Fresenius Names Marc-Alexander Mahl to Management Board and Extends CFO Contract
Fresenius appointed Marc-Alexander Mahl to its management board, and he will oversee Fresenius Kabi from early November. CFO Sara Hennicken's contract now runs five more years, to 2032.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
German healthcare group Fresenius SE said its supervisory board has appointed Dr. Marc-Alexander Mahl to the management board. The company said on Thursday that he will succeed Pierluigi Antonelli, who is stepping down for personal reasons. From early November, Mahl will oversee the Fresenius Kabi businesses, which he has partly handled so far through its pharma and nutrition segments, and he brings more than 20 years of leadership experience inside the group.
Mahl will keep leading the pharma unit, while the nutrition business will be run by Sebastien Guery, given its growing strategic weight. Separately, CFO Sara Hennicken's contract has been extended by another five years and will now run until 2032. The company said these moves put its leadership team in place for the next phase of growth.
why it matters
For investors, leadership changes like these matter as a signal of management stability and how responsibilities are divided across the business. A long extension for the finance chief reduces the risk of losing a key financial executive, while carving out nutrition under its own leader suggests the company sees room for growth there.
tags
instruments
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗